Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving hundreds of leading biopharmaceutical companies globally:

US Department of Justice
Citi
Mallinckrodt
Cipla
Accenture
Express Scripts

Generated: August 21, 2019

DrugPatentWatch Database Preview

Details for Patent: 9,511,193

  Try a free trial


See Plans and Pricing

« Back to Dashboard

Which drugs does patent 9,511,193 protect, and when does it expire?

Patent 9,511,193 protects ADLYXIN and is included in one NDA.

This patent has fourteen patent family members in thirteen countries.

Summary for Patent: 9,511,193
Title:Assembly and indicator for a drug delivery device
Abstract: An assembly for a drug delivery device, comprising a housing having a proximal end and a distal end, a piston rod and an indicator. The piston rod is adapted to be displaced distally with respect to the housing away from a proximal start position and towards a distal end position for delivering a drug. The indicator is adapted for indicating at least two different operation conditions of the assembly, the indicator being movable with respect to the housing from a first indication position for a first condition of the assembly into a second indication position for a second condition of the assembly. The piston rod and the indicator are configured to mechanically interact for converting movement of the piston rod into movement of the indicator. A first detent is provided which is configured to releasably secure the indicator in the first indication position such that movement into the second indication position is allowed. A second detent is provided which is configured to secure the indicator in the second indication position such that movement into the first indication position is prevented.
Inventor(s): Plumptre; David (Droitwich Spa, GB), Terry; Warren (Leaminston Spa, GB), Veasey; Robert (Leamington Spa, GB), Jones; Matthew (Warwick, GB), Claughton; Timothy Giles (Congleton, GB)
Assignee: SANOFI-AVENTIS DEUTSCHLAND GMBH (Frankfurt am Main, DE)
Application Number:13/392,882
Patent Claim Types:
see list of patent claims
Use; Delivery; Device;

Drugs Protected by US Patent 9,511,193

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Sanofi-aventis Us ADLYXIN lixisenatide SOLUTION;SUBCUTANEOUS 208471-001 Jul 27, 2016 RX Yes Yes   Try a Free Trial   Try a Free Trial Y   Try a Free Trial
Sanofi-aventis Us ADLYXIN lixisenatide SOLUTION;SUBCUTANEOUS 208471-002 Jul 27, 2016 RX Yes Yes   Try a Free Trial   Try a Free Trial Y   Try a Free Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Subscribe to access the full database, or try a Free Trial

Foreign Priority and PCT Information for Patent: 9,511,193

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
09171134Sep 23, 2009
PCT Information
PCT FiledSeptember 21, 2010PCT Application Number:PCT/EP2010/063842
PCT Publication Date:March 31, 2011PCT Publication Number: WO2011/036134

International Family Members for US Patent 9,511,193

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 2010299934   Try a Free Trial
Brazil 112012006516   Try a Free Trial
Canada 2772686   Try a Free Trial
China 102510761   Try a Free Trial
Denmark 2480268   Try a Free Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Subscribe to access the full database, or try a Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Julphar
Express Scripts
Chubb
US Army
Citi
Cantor Fitzgerald

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.